Table 1 Characteristic of included studies
Author | Year | Country | IGRAs | Study design | Smear negative/ total TB patients | Confirmed TB patients*N (%) | Immunocompromised | History of tuberculosis N (%) | History of BCG vaccination N (%) | Control subjects | |
|---|---|---|---|---|---|---|---|---|---|---|---|
HIV N (%) | Non-HIV N (%) | ||||||||||
Cattamanchi et al | 2010 | Uganda | QFT | Prospective | 39/126 | 126 (100) | 236 (100) | 0 (0) | NA | NA | Other diseases |
Lee et al | 2010 | South Korea | QFT | Retrospective | 32/32 | 32 (100) | NA | NA | 18 (21) | NA | Other diseases |
Leung et al | 2010 | Hongkong | QFT | Prospective | 188/188 | 121 (64) | 0 (0) | NA | 18 (7) | NA | Other diseases |
SA Kabeer et al | 2010 | India | QFT | Case control | 26/177 | 162 (92) | 0 (0) | 0 (0) | 0 (0) | NA | Healthy |
Ling et al | 2011 | South Africa | Both | Prospective | 46/138 | 138 (100) | 108 (27) | NA | NA | NA | Other diseases |
Lui et al | 2011 | Hongkong | QFT | Prospective | 38/63 | 60 (95) | 2 (1) | 16 (9) | 44(25) | 88(70) | Other diseases |
Jung et al | 2012 | South Korea | Both | Prospective | 39/39 | 60 (95) | 0 (0) | 119 (100) | 24 (20) | 29 (30) | Other diseases |
Taki-Eddin et al | 2012 | Syria | QFT | Unclear | 13/48 | 40 (83) | NA | NA | NA | NA | Other diseases |
Qian et al | 2013 | China | QFT | Case control | 238/458 | NA | NA | NA | NA | NA | Healthy |
Park et al | 2014 | South Korea | QFT | Retrospective | 94/94 | 69 (73) | 0 (0) | 13(14) | 18(19.15) | NA | NA |
Qiu et al | 2015 | China | T-SPOT | Unclear | 382/517 | 224 (59) | 0 (0) | NA | NA | NA | Other diseases and healthy |
Xia et al | 2015 | China | QFT | Prospective | 171/300 | 0 (0) | 1 (0.3) | 0 (0) | 0 (0) | NA | Other diseases and healthy |
Azghay et al | 2016 | France | QFT | Retrospective | 23/60 | 39 (65) | 5 (8) | 5 (8) | NA | NA | Other diseases |
Phetsuksiri et al | 2018 | Thailand | QFT | Case control | 49/102 | 64 (63) | NA | NA | NA | NA | Healthy |
Yang et al | 2018 | China | T-SPOT | Retrospective | 2007/2282 | 640 (28) | 0 (0) | 86 (4) | NA | NA | Other diseases |
Whitworth et al | 2019 | United Kingdom | Both | Prospective | 222/363 | 261 (72) | 135 (16) | 17 (2) | NA | 649 (77) | Other diseases |